TPP1 and neuronal ceroid lipofuscinosis: Incubation with the drug at the concentration of 5.1 μg/mL resulted in both a small, but significant increase in TPP1 activity and the attenuation of neuropathy in NCL patient neuronal progenitor cells derived from induced pluripotent stem cells (iPSCs) [111].